(Q46251633)

20 December 2017

title

Effect of venlafaxine on imipramine metabolism (English)

1 reference

20 December 2017

author name string

Albers LJ

1

1 reference

20 December 2017

Reist C

2

1 reference

20 December 2017

Vu RL

3

1 reference

20 December 2017

Fujimoto K

4

1 reference

20 December 2017

Ozdemir V

5

1 reference

20 December 2017

Helmeste D

6

1 reference

20 December 2017

Poland R

7

1 reference

20 December 2017

Tang SW

8

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

20 December 2017

published in

Psychiatry Research

1 reference

20 December 2017

volume

96

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

page(s)

235-243

1 reference

20 December 2017

Paroxetine shifts imipramine metabolism

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Clinical evaluation of venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Drug-drug interactions involving antidepressants: focus on venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Quantification of imipramine and desipramine in plasma by high-performance liquid chromatography and fluorescence detection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Inhibitors of imipramine metabolism by human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

The pharmacokinetics of venlafaxine when given in a twice-daily regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2800%2900213-4

7 January 2021

10.1016/S0165-1781(00)00213-4

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017